New Directions for Therapeutics in ADHD

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2012 Aug 3

PMID 22855408

Authors

Julie B Schweitzer

Keith McBurnett

Affiliations

Soon will be listed here.

References

McClure S, Laibson D, Loewenstein G, Cohen J . Separate neural systems value immediate and delayed monetary rewards. Science. 2004; 306(5695):503-7. DOI: 10.1126/science.1100907. View

Willcutt E . The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012; 9(3):490-9. PMC: 3441936. DOI: 10.1007/s13311-012-0135-8. View

Stein M, Weiss M, Hlavaty L . ADHD treatments, sleep, and sleep problems: complex associations. Neurotherapeutics. 2012; 9(3):509-17. PMC: 3441938. DOI: 10.1007/s13311-012-0130-0. View

Moriyama T, Polanczyk G, Caye A, Banaschewski T, Brandeis D, Rohde L . Evidence-based information on the clinical use of neurofeedback for ADHD. Neurotherapeutics. 2012; 9(3):588-98. PMC: 3441929. DOI: 10.1007/s13311-012-0136-7. View

Tripp G, Wickens J . Reinforcement, dopamine and rodent models in drug development for ADHD. Neurotherapeutics. 2012; 9(3):622-34. PMC: 3441939. DOI: 10.1007/s13311-012-0132-y. View

Eugene Arnold L, Lofthouse N, Hurt E . Artificial food colors and attention-deficit/hyperactivity symptoms: conclusions to dye for. Neurotherapeutics. 2012; 9(3):599-609. PMC: 3441937. DOI: 10.1007/s13311-012-0133-x. View

Sonuga-Barke E, Halperin J . Developmental phenotypes and causal pathways in attention deficit/hyperactivity disorder: potential targets for early intervention?. J Child Psychol Psychiatry. 2009; 51(4):368-89. DOI: 10.1111/j.1469-7610.2009.02195.x. View

Davis N, Kollins S . Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder. Neurotherapeutics. 2012; 9(3):518-30. PMC: 3441928. DOI: 10.1007/s13311-012-0126-9. View

Rutledge K, van den Bos W, McClure S, Schweitzer J . Training cognition in ADHD: current findings, borrowed concepts, and future directions. Neurotherapeutics. 2012; 9(3):542-58. PMC: 3441933. DOI: 10.1007/s13311-012-0134-9. View

10.

Loo S, Makeig S . Clinical utility of EEG in attention-deficit/hyperactivity disorder: a research update. Neurotherapeutics. 2012; 9(3):569-87. PMC: 3441927. DOI: 10.1007/s13311-012-0131-z. View

11.

Tamm L, Narad M, Antonini T, OBrien K, Hawk Jr L, Epstein J . Reaction time variability in ADHD: a review. Neurotherapeutics. 2012; 9(3):500-8. PMC: 3441931. DOI: 10.1007/s13311-012-0138-5. View

12.

Sonuga-Barke E . Psychological heterogeneity in AD/HD--a dual pathway model of behaviour and cognition. Behav Brain Res. 2002; 130(1-2):29-36. DOI: 10.1016/s0166-4328(01)00432-6. View

13.

Green A, Rabiner D . What do we really know about ADHD in college students?. Neurotherapeutics. 2012; 9(3):559-68. PMC: 3441934. DOI: 10.1007/s13311-012-0127-8. View

14.

Minzenberg M . Pharmacotherapy for attention-deficit/hyperactivity disorder: from cells to circuits. Neurotherapeutics. 2012; 9(3):610-21. PMC: 3441935. DOI: 10.1007/s13311-012-0128-7. View

15.

Halperin J, Bedard A, Curchack-Lichtin J . Preventive interventions for ADHD: a neurodevelopmental perspective. Neurotherapeutics. 2012; 9(3):531-41. PMC: 3441940. DOI: 10.1007/s13311-012-0123-z. View